[New development in bisphosphonate treatment. Review of effect on bone metabolism by minodronic acid in primary osteoporosis].

Abstract

Minodronic acid hydrate is a novel bisphosphonate with stronger anti-resorptive effects, compared to the other existing bisphosphonates. We performed additional analyses of phase III clinical trial and compared the effect of minodronic acid hydrate on bone turnover markers with those of alendronate in primary osteoporosis. The results showed that minodronic acid hydrate suppressed bone turnover early after treatment, and it also was effective in the treatment of patients with prevalent vertebral fracture, which is a high risk for subsequent fracture.

• Authors: Masao Fukunaga
• Journal: Clinical calcium (Clin Calcium) Vol. 19 Issue 1 Pg. 63-73 (Jan 2009) ISSN: 0917-5857 [Print] Japan
• PMID: 19122266 (Publication Type: Comparative Study, English Abstract, Journal Article, Review)

Chemical References

• Amino Acids
• Biomarkers
• Bone Density Conservation Agents
• Collagen Type I
• Diphosphonates
• Imidazoles
• Peptides
• collagen type I trimeric cross-linked peptide
• YM 529
• deoxypyridinoline
• Alendronate

Topics

• Alendronate (pharmacology, therapeutic use)
• Amino Acids (urine)
• Biomarkers (urine)
• Bone Density Conservation Agents (pharmacology, therapeutic use)
• Bone and Bones (metabolism)
• Clinical Trials, Phase III as Topic
• Collagen Type I (urine)
• Diphosphonates (pharmacology, therapeutic use)
• Fractures, Spontaneous (etiology, prevention & control)
• Humans
• Imidazoles (pharmacology, therapeutic use)
• Osteoporosis (diagnosis, drug therapy, metabolism)
• Peptides (urine)